Home › News › Global Pharma

Pfizer Signs USD 2.6 Billion Deal with Starna Therapeutics for In Vivo CAR-T Therapies

Pfizer Signs USD 2.6 Billion Deal with Starna Therapeutics for In Vivo CAR-T Therapies

Pfizer has entered the in vivo CAR-T therapy space through a licensing agreement worth up to USD 2.6 billion with China-based Starna Therapeutics. Under the agreement, Pfizer will acquire ex-China rights to three preclinical in vivo CAR-T programmes being developed for autoimmune diseases.

The agreement includes an upfront payment of USD 330 million, with Starna eligible to receive up to USD 2.3 billion in milestone payments, along with royalties on future product sales. The programmes are currently in pre-Investigational New Drug (pre-IND) development.

Pfizer will lead the clinical development of the three programmes outside Greater China. The company also holds an option to acquire the rights to the programmes in China at a later stage. Pfizer plans to manufacture the drug products for the initial clinical trials at its manufacturing facilities in the United States.

The agreement also provides Pfizer with rights to use the programmes for oncology applications, along with an option to license compounds from a separate collaboration between the companies.

The deal marks Pfizer's first move into in vivo CAR-T therapies, expanding its existing expertise in RNA-based medicines and gene-editing technologies. The company is already collaborating with Beam Therapeutics on gene-editing therapy development.

Michael Vincent, Chief Inflammation and Immunology Officer at Pfizer, said in vivo CAR-T represents an emerging approach to treating autoimmune diseases, particularly for patients who have limited options with existing treatments. He added that Pfizer's experience in developing and manufacturing RNA-based medicines, combined with Starna's technology, would support the development of these therapies.

More news about: global pharma | Published by News Bureau | November - 20 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members